Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial

Shengxiang Ren, Jianxing He, Yong Fang, Gongyan Chen, Zhiyong Ma, Jianhua Chen, Renhua Guo, Xiaoyan Lin, Yu Yao, Gang Wu, Quanren Wang, Caicun ZhouJTO 2022 · DOI

TL;DR

This study investigated a novel, chemotherapy-free combination of camrelizumab (an anti-PD-1 antibody) and apatinib (a VEGFR inhibitor) as a first-line treatment for advanced nonsquamous NSCLC patients with high tumor mutational burden (TMB). The combination demonstrated promising clinical activity and acceptable safety, suggesting a potential new treatment avenue for this patient population.

What Problem Does This Paper Address?

Lung cancer, particularly non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related deaths. While immunotherapy, specifically PD-1/PD-L1 inhibitors, has revolutionized treatment, it's often combined with chemotherapy, which can lead to significant side effects and impact patient quality of life. There's a pressing need for effective chemotherapy-free regimens, especially for treatment-naive patients. Preclinical research suggests that inhibiting angiogenesis (the formation of new blood vessels that tumors need to grow) can enhance the effectiveness of immunotherapies by normalizing the tumor microenvironment. This study aims to evaluate if combining an anti-PD-1 antibody (camrelizumab) with an anti-angiogenic drug (apatinib) can offer a potent and tolerable first-line treatment option for a specific subset of NSCLC patients.

Methods

This was a multicenter, open-label, single-arm, Phase 2 clinical trial. Eligible patients with advanced nonsquamous NSCLC, who had not received prior systemic therapy and had high tumor mutational burden (TMB), were enrolled. The treatment regimen consisted of camrelizumab administered intravenously every two weeks and apatinib taken orally once daily. The primary endpoint was the objective response rate (ORR) as assessed by investigators, using RECIST version 1.1 criteria. Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Tumor response was evaluated regularly via imaging, and adverse events were graded according to standard criteria. TMB was assessed either in tumor tissue or blood.

Datasets

The study utilized data from 25 patients enrolled in a multicenter, open-label, phase 1b and 2 clinical trial conducted in the People's Republic of China. The data collected included patient demographics, clinical characteristics, tumor response assessments, and safety information. No new datasets were introduced; the study focused on analyzing the outcomes of patients treated within this existing trial framework.

Key Insights and Ideas

  • Synergistic Potential of Chemo-Free Combinations: The study reinforces the idea that combining immunotherapy with anti-angiogenic agents can be a potent strategy, potentially offering a chemotherapy-free alternative that maintains efficacy while improving tolerability.
  • TMB as a Predictive Biomarker: The selection of patients with high TMB highlights the growing importance of this biomarker in predicting response to immunotherapy, even in combination regimens.
  • Durable Responses: The observed median duration of response suggests that the benefits of this combination therapy can be long-lasting, which is crucial for improving long-term outcomes in advanced NSCLC.
  • Manageable Safety Profile: Despite the combination of two active agents, the safety profile was deemed acceptable, with a low rate of treatment discontinuation due to adverse events, suggesting a favorable risk-benefit ratio.

Key Results

  • Objective Response Rate (ORR): The study reported an ORR of 40.0% (95% CI: 21.1-61.3), with 10 patients achieving confirmed partial responses.
  • Disease Control Rate (DCR): A high DCR of 92.0% (95% CI: 74.0-99.0) was observed, indicating that the majority of patients experienced either a response or stable disease.
  • Median Progression-Free Survival (PFS): The median PFS was 9.6 months (95% CI: 5.5-not reached).
  • Median Overall Survival (OS): The median OS was not reached at the time of data cutoff, suggesting potential for long-term survival.
  • Safety: All patients experienced at least one treatment-related adverse event (TRAE), with the most common being increased gamma-glutamyltransferase and alanine aminotransferase. Grade 3 or higher TRAEs were reported in 80.0% of patients. Only 4.0% of patients discontinued treatment due to TRAEs.

Limitations and Future Work

The authors acknowledge several limitations, including the small sample size and the lack of a control arm, which are inherent to an early-phase study. The absence of an independent review committee for tumor response assessment is also noted. The high screen failure rate, partly due to the detection of EGFR/ALK mutations and the TMB assessment process, highlights challenges in patient recruitment.

Future work should focus on confirming these promising findings in larger, randomized controlled trials. Further investigation into the role of TMB and other biomarkers to guide treatment selection for this combination therapy is warranted. The authors suggest that the strategy of combining low-dose VEGFR TKIs with PD-1/PD-L1 blockade merits further validation in phase 3 trials, particularly in a broader patient population, including non-Asian patients.

Summary updated

Abstract

Frontline camrelizumab plus low-dose apatinib exhibited promising clinical activity with acceptable safety in patients with advanced nonsquamous NSCLC regardless of PD-L1 expression.
BibTeX
@inproceedings{ren2022camrelizumab,
  author = {Shengxiang Ren and Jianxing He and Yong Fang and Gongyan Chen and Zhiyong Ma and Jianhua Chen and Renhua Guo and Xiaoyan Lin and Yu Yao and Gang Wu and Quanren Wang and Caicun Zhou},
  title = {{Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial}},
  booktitle = {JTO},
  year = {2022},
  doi = {10.1016/j.jtocrr.2022.100312},
}
Figure